Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMPR1B | O00238 | 4/20 | 0.44 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 5/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PRF1 | P14222 | 1/20 | 0.31 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26750443 | 0.83 | BMPR1B (0.43) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL5004930 | 0.81 | BMPR1B (0.42) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL25318279 | 0.81 | BMPR1B (0.42) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL31178355 | 0.81 | BMPR1B (0.42) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL21001754 | 0.81 | BMPR1B (0.45) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL5511206 | 0.80 | BMPR1B (0.41) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL14047350 | 0.79 | BMPR1B (0.41) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL27071706 | 0.79 | BMPR1B (0.41) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL5004920 | 0.76 | KMT2A (0.40) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 | |
| SCHEMBL5001522 | 0.76 | BMPR1B (0.43) | BMPR1BBMPR1AACVRL1ACVR1TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2024360-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON INC (US) | 2013-04-03 | — | — | EP | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2351751-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-7851468-B2 | Substituted pyrazolo[3,4-d]pyrimidines | CEPHALON, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-2024360-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | Cephalon, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008063232-A2 | SUBSTITUTED PYRAZOLOPYRIMIDINES | CEPHALON, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | CEPHALON, INC. (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | BMPR1B 2352/4885BMPR1A 2343/4885ACVRL1 4068/4885 |
| US-20070281949-A1 | Substituted pyrazolopyrimidines | DPYD, P2RX5, P2RX6 | BMPR1B 2793/4885BMPR1A 2961/4885ACVRL1 4009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.